Clinical implications of free triiodothyronine levels and diagnostic revisions in antibody-negative autoimmune encephalitis
-
By
-
Ting Fang
-
Xinjie He
-
Junling Chen
-
Linhuan Huang
-
Yingyu Xie
-
Danni Li
-
Yinting Huang
-
Qi Lin
-
Houshi Zhou
-
July 7, 2026
-
Clinical Scorecard: Clinical Significance of Free Triiodothyronine Levels and Diagnostic Reassessment in Antibody-Negative Autoimmune Encephalitis
At a Glance
| Category | Detail |
|---|
| Condition | Antibody-Negative Autoimmune Encephalitis |
| Key Mechanisms | Low triiodothyronine (T3) syndrome associated with clinical severity and outcomes. |
| Target Population | Patients diagnosed with antibody-negative autoimmune encephalitis. |
| Care Setting | Retrospective cohort study in a clinical hospital setting. |
Key Highlights
- 23.68% of patients presented with low T3 syndrome during the acute phase.
- Low T3 syndrome correlated with higher incidence of consciousness disturbances and motor impairments.
- Discharge modified Rankin Scale (mRS) scores were independent predictors of unfavorable outcomes.
- 8 out of 84 patients were reclassified with alternative diagnoses after follow-up.
- 61.84% of patients achieved a favorable prognosis.
Guideline-Based Recommendations
Diagnosis
- Consider re-evaluation for patients with antibody-negative AE showing clinical red flags.
Management
- Monitor neurological function using modified Rankin Scale (mRS) during hospitalization and follow-up.
Monitoring & Follow-up
- Assess thyroid hormone levels as part of the clinical evaluation.
Risks
- Misdiagnosis may lead to delays in appropriate immunotherapy.
Patient & Prescribing Data
84 Chinese Han patients initially suspected of having antibody-negative AE.
Low T3 syndrome may reflect disease severity rather than serve as an independent prognostic biomarker.
Clinical Best Practices
- Utilize mRS scores for evaluating neurological outcomes.
- Conduct thorough follow-up assessments to identify potential reclassifications.
Related Resources & Content
